4 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
Follow H56:IC31: new trials by email Literature Review of H56:IC31 trials Research Report on H56:IC31
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic etoricoxib, H56:IC31 - Tuberculosis | Phase 1 | Completed | Anne Margarita Dyrhol Riise | 39 | 2015-11-01 | 2022-04-08 |
| Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents H4:IC31, H56:IC31, BCG - Tuberculosis | Phase 1 | Completed | Aeras | 84 | 2015-05-01 | 2019-11-18 |
| A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB H56:IC31, Placebo - Tuberculosis | Phase 1 | Completed | Aeras | 22 | 2014-11-21 | 2024-07-30 |
| Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis H56:IC31 - Latent Tuberculosis, Latent Tuberculosis Bacteriology and Histology Unknown | Phase 1 | Completed | Aeras | 25 | 2011-11-01 | 2019-08-21 |
Tuberculosis (3) · Latent Tuberculosis (1)
Aeras (3) · Anne Margarita Dyrhol Riise (1)
South Africa (3) · Norway (1)
Angelique Luabeya, MD (1) · Anne Margarita Dyrhol-Riise, PhD (1) · Dereck Tait, MBChB (1) · Jim Kublin, MD (1) · Linda-Gail Bekker, MD (1)
PMID 30888024, PMID 32382714, PMID 34811370, PMID 37721470
2014 (1)